SAN FRANCISCO, CA — May 6, 2026 — Leads & Copy — Immusoft of CA, a clinical-stage biotechnology company, announced that its Chief Development Officer, Scott McIvor, will present recent clinical data at the American Society of Cell and Gene Therapy (ASGCT) 29th Annual Meeting in Boston, MA, from May 11-15, 2026.
The poster presentation will focus on the company’s engineered B cell therapy, ISP-001, and its potential for treating patients with MPS I (Mucopolysaccharidosis type I).
Sean Ainsworth, Chief Executive Officer of Immusoft, expressed pleasure in sharing data that reinforces the potential of ISP-001 as a differentiated approach for MPS I patients. He noted favorable safety and tolerability observations, alongside encouraging biochemical activity, including the ability to safely re-dose patients. These results support continued development of ISP-001 in adult patients and the planned expansion into pediatric populations.
The trial is supported by up to $23 million in funding from the California Institute for Regenerative Medicine (CIRM).
MPS I is a rare, lethal childhood genetic disease affecting the body’s ability to produce IDUA (alpha-L-iduronidase), an essential enzyme in the breakdown of sugar molecules called glycosaminoglycans (GAGs). The inability to break down GAGs leads to their accumulation in cells, causing organ damage and early death. It occurs in approximately 1 in 100,000 live births, with symptoms appearing within the first year of life for the most severe form, Hurler Syndrome. Children affected with the Hurler form of MPS I rarely live more than ten years after diagnosis, if left untreated.
ISP-001 is designed to secrete therapeutic levels of α-L-iduronidase (IDUA), the enzyme deficient in MPS I patients, by deploying a patient’s own cells to function as “living biofactories”. ISP-001 aims to overcome challenges associated with current therapies, including the “sawtooth effect” and safety concerns associated with stem cell transplants.
ISP-001 has received Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the U.S. Food and Drug Administration and is currently being evaluated in a Phase 1/2 clinical trial (NCT05682144).
Immusoft of CA is a wholly owned subsidiary of Immusoft Corporation, a clinical-stage company developing novel therapies for rare diseases using sustained delivery of protein therapeutics from a patient’s own cells. The company has developed a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines.
Source: Immusoft
